References
- 1. Bansal, V, J Kalita, and U K Misra. “Diabetic Neuropathy.” Postgraduate Medical Journal 82.964 (2006): 95–100. PMC. Web. 27 June 2018.
- 2. Juster-Switlyk, Kelsey, and A. Gordon Smith. “Updates in Diabetic Peripheral Neuropathy.” F1000Research 5 (2016): F1000 Faculty Rev–738. PMC. Web. 27 June 2018.
- 3. Román-Pintos, Luis Miguel et al. “Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.” Journal of Diabetes Research 2016 (2016): 3425617. PMC. Web. 27 June 2018.
- 4. Antonio Ayala, Mario F. Muñoz, and Sandro Argüelles, “Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 360438, 31 pages, 2014
- 5. Mahreen, Rashida et al. “Significantly Increased Levels of Serum Malonaldehyde in Type 2 Diabetics with Myocardial Infarction.” International Journal of Diabetes in Developing Countries 30.1 (2010): 49–51. PMC. Web. 27 June 2018.
- 6. Shay, Kate Petersen et al. “Alpha-Lipoic Acid as a Dietary Supplement: Molecular Mechanisms and Therapeutic Potential.” Biochimica et biophysica acta 1790.10 (2009): 1149–1160. PMC. Web. 27 June 2018.
- 7. Vallianou, Natalia, Angelos Evangelopoulos, and Pavlos Koutalas. “Alpha-Lipoic Acid and Diabetic Neuropathy.” The Review of Diabetic Studies : RDS 6.4 (2009): 230–236. PMC. Web. 30 June 2018.
- 8. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M. et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006;29:2365–2370.17065669
- 9. Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ, Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes?, Neth J Med. 2010 Apr;68(4):158-62.20421656